» Articles » PMID: 678428

Coagulation and Fibrinolysis During the Infusion of Corynebacterium Parvum in Man

Overview
Journal Br J Cancer
Specialty Oncology
Date 1978 Jun 1
PMID 678428
Citations 4
Authors
Affiliations
Soon will be listed here.
Citing Articles

Effect of intravenous corynebacterium parvum on peripheral-blood effector cells of cancer patients.

Gill P, Waller C, MacClennan I, Morris P Br J Cancer. 1980; 41(5):782-9.

PMID: 7426303 PMC: 2010321. DOI: 10.1038/bjc.1980.142.


Single versus multiple human-equivalent doses of C. parvum in mice: neutralization of the anti-metastatic effect.

Mitcheson H, Sadler T, Castro J Br J Cancer. 1980; 41(3):407-14.

PMID: 7387830 PMC: 2010249. DOI: 10.1038/bjc.1980.64.


Mechanisms of C. Parvum-induced coagulopathy in mice.

Mitcheson H, Hilgard P, McCraw A, Castro J Br J Cancer. 1980; 41(1):117-22.

PMID: 7362773 PMC: 2010159. DOI: 10.1038/bjc.1980.13.


Hypercoagulability after immunotherapy with Corynebacterium parvum in man.

Harenberg J, Baumgartner A, Fritze D, Zimmermann R Blut. 1982; 44(4):241-7.

PMID: 7082858 DOI: 10.1007/BF00319910.

References
1.
Gans H . FIBRINOLYTIC PROPERTIES OF PROTEASES DERIVED FROM HUMAN, DOG AND RABBIT LEUKOCYTES. Thromb Diath Haemorrh. 1964; 10:379-89. View

2.
Hughes L . TREATMENT OF MALIGNANT DISEASE WITH PROTAMINE SULPHATE. Lancet. 1964; 1(7330):408-9. DOI: 10.1016/s0140-6736(64)92787-4. View

3.
CLIFFTON E, Agostino D . Factors affecting the development of metastatic cancer. Effect of alterations in clottin mechanism. Cancer. 1962; 15:276-83. DOI: 10.1002/1097-0142(196203/04)15:2<276::aid-cncr2820150211>3.0.co;2-g. View

4.
Sherry S, LINDEMEYER R, Fletcher A, ALKJAERSIG N . Studies on enhanced fibrinolytic activity in man. J Clin Invest. 1959; 38(5):810-22. PMC: 293227. DOI: 10.1172/JCI103863. View

5.
ASTRUP T, Mullertz S . The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys. 1952; 40(2):346-51. DOI: 10.1016/0003-9861(52)90121-5. View